ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP

BAUDETTE, Minn., June 27, 2018 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market ... Biopharmaceuticals, Product Launch ANI Pharmaceuticals, cholestyramine, hypercholesterolemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news